Pure Global

Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 - Trial NCT06410131

Access comprehensive clinical trial information for NCT06410131 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sound Biopharmaceuticals Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 68 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06410131
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06410131
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Dose Expansion Study of FTL008.16, a Recombinant Anti-CD137 and Anti-5T4 Bispecific Antibody, in Patients With Advanced or Metastatic Solid Tumors

Study Focus

Solid Tumors

FTL008.16

Interventional

drug

Sponsor & Location

Sound Biopharmaceuticals Ltd.

Beijing, China

Timeline & Enrollment

Phase 1

Jun 01, 2024

May 01, 2027

68 participants

Primary Outcome

Number of participants with dose-limiting toxicities (DLTs)

Summary

This is an open, multi-center, multi-cohort phase I clinical study designed to evaluate
 safety, tolerability, pharmacokinetics and initial efficacy of FTL008.16 in patients with
 advanced and metastatic solid tumors.

ICD-10 Classifications

Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm of other connective and soft tissue
Carcinoma in situ, unspecified
Malignant neoplasms
Malignant neoplasm: Parametrium

Data Source

ClinicalTrials.gov

NCT06410131

Non-Device Trial